头颈部肿瘤多药耐药机制及逆转剂研究进展
总之，经过对MDR机制的深入研究，现在已取得了一些重要发现，在其临床如何克服MDR方面也取得一定进展，但其效果不尽人意。而且对于头颈部肿瘤的MDR研究仍较少，有关逆转剂的报道也不多。因此，对于头颈部MDR逆转剂的研究是今后我们克服化疗耐药研究的主要方向之一。
［参考文献］
［1］ Filer JS, Underhill LH. Multiple-drug resistance in human cancer［J］. N Engl J Med, 1987, 316:1388-1393.
［2］ Ford JM. Modulators of multidrug resistance［J］. Hematol Oncol North Am, 1995, 9:337-361.
［3］ Goldstein LJ. Clinical reversal of drug resistance［J］. Curr Probl Cancer, 1995, 3:70-123.
［4］ Rabkin D, Chhieng DC, Miller MB, et al. P-glycoprotein expression in squamous cell carcinomas of the tongue base［J］. Laryngoscope, 1995, 105:1294-1299.
［5］ Kelley DJ, Pavelic ZP, Gapany M, et al. Detection of P-glycoprotein in squamous cell carcinomas of the head and neck［J］. Arch Ortolaryngol Head Neck Surg, 1993, 19:411-414.
［6］ Jain V, Das SN, Luthra K, Shukla NK, Ralhan R. Differential expression of multidrug resistance gene product, P-glycoprotein, in normal, dysplastic and malignant oral mucosa in India［J］. Int J Cancer, 1997, 74:128-133.
［7］ Yuen AR, Sikic BI. Multidrug resistance in lymphomas［J］. J Clin Onclo, 1994, 12:2453-2459.
［8］ Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-s-transferase in recurrent lymphomas: The possible role of epstein barr virus, immunophenotypes, and other predisposing factors［J］. J Clin Oncol, 1993, 11:109-115.
［9］ Niehans GA, Jaszcz W, Brunetto V, et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lyphomas［J］. Cancer Res, 1992, 52:3768-3775.
［10］ Kang YK, Zhan Z, Regis J, et al. Expression of mdr-1 in refractory lymphoma: quantitation by polymerase china reaction and validation of the assay［J］. Blood, 1995, 86:1515-1524.
［11］ Perez RP, Hamilton TC, Ozols RF. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems［J］. Pharmacol Ther, 1990, 48:19-27.
［12］ Bongers V, Snow GB, deVries N, et al. Second primary head and neck squamous cell carcinoma predicted by the glutathione s-transferase expression in healthy tissue in the direct vicinity of the first tumor［J］. Lab Invest, 1995,73:503-509.
［13］ Welters MJP, Fichitnger-Schepman AMJ, Baan RA, Fleno MJ, Scheper RJ, Breahhuis BJM. Role of glutathone, glutathione s-transfereases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines［J］. Br J Cancer, 1998, 77:556-561.
［14］ Muller M, Meijer C, Zaman GJR. et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione s-conjugate transport［J］. Proc Natl Acad Sci USA, 1994, 91:13033-13037.
［15］ Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance［J］. Hematol Oncol North Am, 1995, 9:363-382.
［16］ Klopman G, Shi LM, Ramu A. Quantitative structure-activity relationship of multidrug resistance reversal agents［J］. Mol Pharmacol, 1997, 52:323-334.
［17］ Sikic BI. Modulation of multidrug resistance: at the threshold［J］. J Clin Oncol, 1993, 11:1629-1635.
［18］ Wilson WH, Jamis-Dow C, Bryant G, et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy［J］. J Clin Oncol, 1995, 13: 1985-1994.
［19］ Wilson WH, Bates S, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy［J］. J Clin Oncol, 1995, 13:1995-2004.
- 上一篇：抗癌新药奥沙利铂治疗晚期大肠癌
- 下一篇：洛美沙星眼药水治疗眼部感染104例
